Clinical trials: TNBC - Triple-Negative Breast Cancer
Estrogen Receptor-negative Breast Cancer, HER2-negative Breast Cancer
Nab-Paclitaxel and Bevacizumab Followed By Bevacizumab and Erlotinib in Metastatic Breast Cancer
This phase II trial studies how well giving paclitaxel albumin-stabilized nanoparticle (Nab-paclitaxel) formulation together with bevacizumab followed by bevacizumab and erlotinib hydrochloride work in treating patients with…
- Conditions
- Estrogen Receptor-negative Breast Cancer, HER2-negative Breast Cancer, Progesterone Receptor-negative Breast Cancer, Recurrent Breast Cancer
- Trial name
- NCT00733408
- Testing
- paclitaxel albumin-stabilized nanoparticle formulation, bevacizumab, erlotinib hydrochloride
- Where
- 17 sites in United States
- Volunteers
- 59 people
- Sponsor
- University of Washington
Breast Neoplasm, Breast Neoplasm, Male
Pre-operative IRX-2 in Early Stage Breast Cancer (ESBC)
The goal of this study is assess the safety and tolerability of the IRX-2 regimen in patients with early stage breast cancer (ESBC) and to estimate the pathologic complete response rate to neoadjuvant anthracycline-based and…
- Conditions
- Breast Neoplasm, Breast Neoplasm, Male, Triple Negative Breast Cancer
- Trial name
- NCT02950259
- Testing
- Cyclophosphamide, Indomethacin, Omeprazole
- Where
- United States
- Volunteers
- 16 people
- Sponsor
- Providence Health & Services